Liso-Cel Demonstrates Durable Efficacy in Relapsed/Refractory CLL/SLL
Lisocabtagene maraleucel elicited durable responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Source: onclive.com
Niravn Shah News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Niravn Shah. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Niravn Shah Today - Breaking & Trending Today
Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL
Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.
Source: onclive.com
Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma
Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.
Source: onclive.com
Standards of Care and Novel Therapies Converge to Propel Advances in Follicular Lymphoma
Christopher R. Flowers, MD, MS, and colleagues shed light on recent updates in the treatment armamentarium for follicular lymphoma and highlight ongoing investigations of novel agents and combinations.
Source: onclive.com
Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase...
Source: prnewswire.com